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Abstract:  
Introduction: The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) seeks to 
reduce healthcare disparities by providing uninsured and underinsured women access to screening 
mammograms. The objective of this study is to identify the differences in presentation, surgical 
management and mortality among non-metastatic uninsured patients diagnosed through Indiana’s Breast 
and Cervical Cancer Program (IN-BCCP) compared to patients with private and government (Medicare or 
Medicaid) insurance.  
Methods: Study data was obtained using the Indiana state cancer registry and IN-BCCP.  Women ages 
50-64 with an index diagnosis of stage 0-III breast cancer from January 1st, 2006 to December 31, 2013, 
were included in the study. Bivariate intergroup analysis was conducted. Kaplan Meier estimates between 
insurance types were compared using the log rank test. All-cause mortality was evaluated using a mixed 
effects model.  
Results: The groups differed significantly for sociodemographic and clinical variables. Uninsured IN-
BCCP patients presented with later disease stage (p < 0.001) and had the highest overall mortality (HR 
2.2, p = 0.003). Surgical management only differed among stage III patients (p = 0.012).  
Conclusion: To improve insurance-based disparities in Indiana, implementation of the BCCP in 
conjunction with expansion of insurance coverage to vulnerable low-income populations need to be 
optimized. 
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Introduction: 
Since the implementation of the Patient Protection and Affordable Care Act (ACA), insurance 
and access to healthcare have been at the forefront of national discourse.  For breast cancer patients, 
insurance status has been linked to disparities in stage of presentation, treatment and survival. 1-3   For 
women who are uninsured, underinsured or underserved, the National Breast and Cervical Cancer Early 
Detection Program (NBCCEDP), managed by the Centers for Disease Control and Prevention, provides a 
means to undergo free screening mammography and receive subsequent treatment through state funded 
insurance.4 The Indiana Breast and Cervical Cancer Program (IN-BCCP) is the state’s iteration of the 
NBCCEDP.  
Criteria for entry into the IN-BCCP screening mammography program includes (1) age 50-64 
years, (2) lack of healthcare coverage for screening mammography, and (3) income up to 200% of the 
federal poverty level.5 Patients meeting criteria for participation in the program ,who ultimately are 
diagnosed with breast cancer, are eligible for Medicaid (MA 12) under the Indiana Breast and Cervical 
Cancer Treatment Act. 
 To date, most studies evaluating the NBCCEDP have focused on comparing presentation, 
treatment and clinical outcomes, such as all-cause and cancer specific mortality, between breast cancer 
patients diagnosed through NBCCEDP and non-NBCCEDP patients in state cancer registries6-8.  
However, few studies have evaluated NBCCEDP and non-NBCCEDP data through the lens of insurance 
status at diagnosis.8 Reviewing the data with a focus on insurance status at diagnosis improves our 
understanding of how access to screening by the NBCCEDP mitigates insurance-based disparities in 
disease presentation and clinical outcomes.  To this end, the objective of this study is to understand the 
differences in presentation, surgical management and all-cause mortality between uninsured IN-BCCP 
breast cancer patients at diagnosis and privately or government insured patients in the Indiana cancer 
registry. We hypothesize that utilization of the IN-BCCP by uninsured low-income Hoosiers will result in 
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equivalent stage of presentation, surgery use and similar all-cause mortality when compared to privately 
insured, Medicare and Medicaid patients.  
Methods:  
This study is an observational cohort study of breast cancer patients identified in both the Indiana 
State Cancer Registry (ISCR) and IN-BCCP, maintained by the Indiana State Department of Health.  The 
Indiana Network for Patient Care (INPC) was used to supplement data collected in the state cancer 
registry; the INPC is a state level database with access to the electronic medical records of multiple 
healthcare systems in Indiana.9 
Population:   
Women ages 50-64 (at time of diagnosis) with stage 0-III breast cancer diagnosed between 
January 1, 2006, and December 31, 2013, were identified in both the ISCR and IN-BCCP. The 50-64 age 
range encompasses the age eligibility criteria for participation in breast cancer screening though the IN-
BCCP. 
Measures:  
The sociodemographic variables assessed included insurance type at diagnosis, area of residence 
(urban versus rural), age, race/ethnicity (black, white other), area poverty level (based on county census 
level data), and education (based on county census level data).  The insurance types at diagnosis evaluated 
were uninsured (IN-BCCP), private, Medicaid, and Medicare. The uninsured group were those who were 
enrolled in the IN-BCCP. 
Race/ethnicity groups designated as Asian, Native American, Pacific Islander and other were 
aggregated into a single “other” category due to their small numbers. The poverty level was divided into 
three groups based on the percentage of residents in the patient’s zip code living below the poverty level. 
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The groups included—low (3.9%- 14.5%), moderate (14.6%-18.3%) and high (18.4% -24.7%).  
Comorbidities were classified according to the Charlson Deyo morbidity index (0, 1-2, ≥3). 
Clinical variables of interest included pathologic stage 0-III (based on AJCC 6th edition), estrogen 
receptor status [ER], progesterone receptor status [PR] and human epidermal growth factor receptor 2 
status [Her-2]). We excluded stage 0 patients from our tabulation of Her 2-receptor status, as this is not 
routinely performed in patients with ductal carcinoma in situ.  Due to the small proportion of subjects 
with stage II breast cancer in the IN-BCCP (2% of the eligible population), stage I and II patients were 
combined into a single group. Surgery type was divided into breast conservation surgery (BCS), 
mastectomy and no surgery.  BCS included partial mastectomy, lumpectomy and excisional biopsy. 
Analysis 
Bivariate intergroup analysis evaluating differences in sociodemographic variables, clinical 
variables and surgical management were conducted using chi squared, student T tests, and ANOVA, 
followed by Tukey’s pairwise comparison of the means as appropriate.  Subgroup bivariate analysis 
comparing differences in surgery type were stratified by stage. 
Survival analysis among stage I-III breast cancer patients was conducted using Kaplan Meier 
estimates at 3 years and 5 years, using the outcome of all-cause mortality. Stage 0 patients were omitted 
due to a high survival rate in this cohort. The four insurance types at diagnosis were compared using the 
log rank test. A mixed-effect survival model was created to better define the relationship between all-
cause mortality and insurance status at diagnosis.  We used a mixed-effects parametric survival model 
that allowed us to control for the clustering effect at the county level, due to poverty and education level 
data coming from the same county. Variables in the model included insurance type, race/ethnicity, 
poverty group (low, moderate, high), education, area of residence, surgery type, receipt of radiation, 
pathologic stage, and comorbidities.  The variables in the model were selected due their acceptance in the 
literature as variables that affect mortality among breast cancer patients.6,7,10 All statistical analyses were 
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performed in Stata software version 14.2. 
Results: 
Study Population Description 
The study population included 1462 patients from ages 50-64 years with stage 0-III breast cancer 
diagnosed from 01/01/2006 through 12/31/2013.  The distribution of insurance at diagnosis included: IN-
BCCP 350 (23.9%), private insurance 786 (53.8%), Medicaid 162 (11.1%), and Medicare 164 (11.2%). 
The majority of patients in the study were white 1196 (81.8%), with no comorbidities 1317 (90%), had 
obtained a high school diploma 86.5%, and resided in an urban area 1139 (78%).  The population was 
evenly distributed among the three poverty groups of low 491 (33.6%), moderate 496 (34%) and high 474 
(32.44%) (Table 1).  
Disease Presentation and Surgical Management between Insurance Groups 
 The insurance groups differed on stage at presentation (p <0.001). Specifically, a higher 
percentage of IN-BCCP patients presented with stage III disease compared to Medicare, Medicaid and 
private insurance.  There was a significant difference between insurance groups on hormone receptor 
status ER (P <0.001), PR (P <0.001), and Her-2 status (P <0.001), with IN-BCCP presenting with highest 
incidence of Her-2 positive disease (Table 2). 
 Bivariate analysis showed a significant difference between the groups on surgery type (BCS vs 
Mastectomy) (Table 3).  However, when the data was stratified by stage, the difference in surgery type 
only persisted among stage III patients (p= 0.012) (not shown).  
Subset analysis conducted among BCS patients to evaluate radiation therapy use showed no 
difference between the insurance groups on receipt of radiation therapy after BCS (p=0.873) (Table 3). 
All-cause Mortality Differences by Insurance Group 
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 On Kaplan-Meier analysis, IN-BCCP patients had the worst all-cause mortality (p = 0.000) 
(Figure 1).  The divergence of all-cause mortality among the IN-BCCP from the other insurance types 
started at 3-years (p.= 0241) (Figure 2) and continued at 5-years (p = 0.0204) (Figure 3). 
 On multivariable analysis, the difference in all-cause mortality between patients within the IN-
BCCP and those with private or government insurance persisted, as shown in Table 4. With private 
insurance as the reference group, patients in the IN-BCCP had the highest all-cause mortality [HR 2.2, 
(95% CI 1.3, 2.6), p=0.003] compared to those with Medicaid [HR 1.4, (95% CI 0.9, 202), p=0.216] and 
Medicare [1.4 (95% CI 0.8, 2.6), p=0.257]. Lack of surgery [HR 2.9, (95%CI 1.5, 5.9), p=0.001] and 
presence of multiple comorbidities [HR 2.6, (95%CI 1.4, 4.5), (p= 0.001)] were also associated with an 
increased all-cause mortality.  
Discussion 
This study is the first to evaluate the differences in presentation, surgical management, and mortality 
among uninsured non-metastatic breast cancer patients diagnosed through the IN-BCCP, compared to 
those with private or government insurance. NBCCEDP programs, such as the IN-BCCP are designed to 
reduce healthcare disparities by increasing access to breast and cervical cancer screening among  
underserved women.4 For breast cancer patients, access to screening mammography is vital for early 
detection and improved survival.11 While these programs receive a combination of federal and state 
funding, they are exclusively administered by state governments.  Therefore, evaluation of the success of 
these individual programs at the state level is important to understand how different local contexts affect 
the impact of the program. In addition, knowledge of the influence of insurance status at diagnosis on 
clinical outcomes may inform future state policy and health insurance resource allocation. 
Our finding of uninsured IN-BCCP patients presenting with a more advanced cancer stage is 
consistent with other studies evaluating insurance-based disparities and stage of presentation among 
breast cancer patients. 2,12,13 In their examination of breast cancer patients in the National Cancer 
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Database, Halpern et al demonstrated that uninsured patients or patients with Medicaid were more likely 
to present with stage II-IV disease than stage I, when compared to their privately-insured counterparts.14  
Hsu et el. confirmed this finding with their evaluation of the Surveillance Epidemiology End Result 
database, noting patients with Medicaid and the uninsured presented with a later stage disease compared 
to the privately insured15. Possible explanations for later disease presentation among the uninsured or 
Medicaid patients are lack of access to screening or infrequent use of screening services. 14 However, 
since our uninsured population participated in a program intended to increase screening access, the 
disparity in stage may reflect patients using the program when symptomatic, or alternatively, being more 
likely to be develop aggressive types of breast cancer that develop within established screening intervals.  
There is heterogeneity in the literature regarding the association between insurance and surgical 
treatment.  Yet in general, patients with private insurance have higher rates of BCS than their government 
(Medicare, Medicaid) insured or uninsured counterparts. 1,12,16,17 In our study, bivariate analysis showed 
significant differences in surgery type between the insurance groups.  Nevertheless, when stratified by 
stage, only stage III breast cancer patients differed significantly on surgery type. Specifically, stage III 
IN-BCCP patients were the least likely to undergo mastectomy compared to private, Medicaid and 
Medicare insurance (not shown).   This result prompted further analysis evaluating the use of radiation 
therapy among all patients who underwent BCS. The analysis revealed no difference between the 
insurance groups in the use of radiation therapy thus indicating insurance type did not appear to affect 
receipt of the standard of care of BCS plus radiation therapy. This is meaningful as studies have shown a 
combination of BCS and radiation therapy improve disease specific survival.18  The eligibility for Indiana 
Medicaid (MA-12) for BCCP patients was enacted in 2009.  Since this study covers the period between 
2006 through 2013, a segment of the population was affected by the 2009 Medicaid expansion to the 
BCCP population. Thus, it is possible that patients who were enrolled in Medicaid gained increased 
access to radiation therapy, thus explaining the lack of a significant difference in the use of radiation 
therapy among patients undergoing BCS across insurance types.  Future studies of Medicaid expansion in 
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Indiana should evaluate differences in outcomes before and after expansion of Medicaid among breast 
cancer patients. 
Multiple studies have confirmed early detection through screening mammography improves mortality 
among breast cancer patients.11 As stated previously, state programs supported by the NBCCEDP aim to 
improve access in the hopes of improved outcomes. In our unadjusted Kaplan-Meier analysis we noted a 
divergence in all-cause mortality between the insurance types starting at 3 years from diagnosis. IN-
BCCP patients had worse mortality than private, Medicare or Medicaid patients at 3 years from diagnosis. 
This difference in all-cause mortality was confirmed in multivariate analysis (HR 2.2). The association 
between worsening all-cause mortality and lack of insurance is consistent with other studies evaluating 
insurance-based healthcare disparities.13,19 However, our state-based finding of no difference in all-cause 
mortality between Medicaid and privately insured breast cancer patients indicates that having some type 
of insurance at diagnosis may diminish disparities in clinical outcomes.  
 One potential explanation for the disparities in survival between insurance types could be the 
possibility of more symptomatic breast cancer (i.e. presenting with a palpable mass) among the BCCP 
patients. Studies indicate cancers discovered on screening mammography are smaller and less likely to be 
node positive, subsequently resulting in a shift to earlier stages at presentation, in conjunction with more 
favorable overall and breast cancer specific survival.20-22  Therefore, if we speculate that more BCCP 
patients, compared to other insurance types, are receiving diagnostic mammography as their index 
imaging modality, one could argue they are less likely to benefit from mammography.  Nonetheless, the 
benefits of screening mammography may be overestimated due to length time bias and lead time bias.23,24 
Furthermore, the absolute benefit of screening is small with a Cochrane review showing 1 death avoided 
for every 2000 women screened.25  For this study, we believe the difference in all-cause mortality 
between the IN-BCCP and their insured counterparts is most likely multifactorial and may include an 
interplay among greater unmet medical needs, socioeconomic stress, and delays in pursing treatment once 
diagnosed.10,26-28.  Future studies should consider tracking how long patients have been screened in 
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different breast cancer screening programs, or insurance programs for that matter, to better understand 
whether any cancers diagnosed were based upon first-time or interval screenings, which may be 
associated with different prognoses. 
Limitations 
We anticipate the level of awareness--and subsequent referrals--to the IN-BCCP by patients, 
healthcare providers and health systems may be the driving force behind patient enrollment in the 
BCCP.  As a result, these varying levels of awareness may result in a selection bias in this cohort.  
Another limitation of the study dataset is our inability to verify the use of chemotherapy and hormone 
therapy in the study population.  Both modalities have been shown to improve survival in breast cancer 
patients so full adjustment for these factors could affect our results.  
The cancer registry also does not ascertain if patients’ breast abnormality were detected on 
physical exam by the patient or physician.  Furthermore, the registry does not clarify if the first imaging 
modality was screening or diagnostic mammography. This information would have been useful in 
understanding if the differences in stage of presentation and survival were due to difference in 
presentation (symptomatic vs asymptomatic).   
The study evaluated all-cause mortality because breast cancer specific mortality was not available 
for the dataset. As a result, differences in breast cancer specific mortality may still be present. In addition, 
the absolute benefits of mammography are very small, and our sample may not be adequately powered to 
reflect that benefit. Nonetheless, because all-cause mortality is not affected by bias in classifying the 
cause of death, it is an important outcome to measure in cancer screening programs.29 Finally, the 
interpretation of differences in hormone receptor status should be made with caution due the high level of 
missingness, approximately 50%, due to changes in the data elements routinely collected by the cancer 
registry over time. 
Conclusion 
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Low-income individuals are among the most sensitive to changes in insurance policy due to 
significant insurance-based disparities in healthcare access and clinical outcomes.  This study helps to 
better understand the impact of a federally-funded, state-administered cancer screening program upon 
insurance-based disparities and whether participation in the program mitigates prior lack of insurance.  
Based on the data presented here, breast cancer patients in Indiana utilizing the BCCP program have a 
worse all-cause mortality and are more likely to present with a later stage of breast cancer than patients 
with private or government insurance. Our findings indicate that outcomes for breast cancer patients with 
Medicaid at diagnosis differ from those with IN-BCCP, suggesting that further expansion of health 
insurance in the state may lead to earlier detection and improved survival. 
Additional consideration may also be directed towards promotion and implementation of 
programs such as the IN-BCCP to insure the timely receipt of screening, or perhaps expand services 
beyond screening alone. Current estimates from the Indiana State Department of Health (ISDH) indicate 
that in 2014 over one quarter of Hoosier women were eligible for cervical or breast screening through the 
IN-BCCP.  From 2011-2017, 4,275 women underwent clinical breast exam, mammography or ultrasound 
evaluation using BCCP resources.  Of these, 2,800 women underwent screening mammography through 
the program.30 Therefore, only a very small fraction of those eligible for the IN-BCCP participated in the 
program.  Without universal insurance, IN-BCCP clearly remains a necessary option of last resort to 
enable access to community-based breast cancer screening. 
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Table 1: Study Population Sociodemographic Variables by Insurance Status at Diagnosis* 
Variables Total Sample 
 
IN-BCCP 
 
 
Medicaid 
 
Medicare 
 
Private  
Insurance 
 
P-
value 
Total Patients 1462 350 162 164 786  
Age 
Mean (years) 
Median (years) 
 
57.3 
57.2 
 
56.8 
56.6 
 
 
57.1 
57 
 
57.1 
57 
 
57.1 
57 
 
<0.001 
Comorbidities 
0 
1-2 
≥3 
 
1317 (90) 
138 (9.4) 
7 (0.5) 
 
 
315 (90) 
33 (9.4) 
2 (0.6) 
 
140 (86.4) 
21 (13) 
1 (0.6) 
 
129 (78.7) 
31 (19) 
4 (2.4) 
 
733(93.3) 
53 (6.7) 
0 
<0.001 
Race 
White 
Black  
Other 
 
1196 (81.8) 
252 (17.2) 
14 (1) 
 
 
297 (84.9) 
47 (13.4) 
6 (1.71) 
 
108 (66.7) 
53 (32.7) 
1 (0.6) 
 
 
106 (64.6) 
58 (35.4) 
0 
 
685 (87.1) 
94 (12) 
7 (0.9) 
 
<0.001 
Poverty Status 
Low 
Moderate 
High 
 
491 (33.6) 
196 (34) 
474 (32.4) 
 
181 (51.7) 
109 (31.1) 
60 (17.4) 
 
 
22 (13.6) 
68 (42) 
72 (44.4) 
 
 
24 (14.6) 
65 (39.6) 
75 (45.7) 
 
264 (33.6) 
254 (32.4) 
267 (34) 
<0.001 
Metro Status† 
Rural 
Urban 
unknown 
 
286 (19.6) 
1139 (78) 
37 (2.5) 
 
 
80 (22.9) 
270 (77.1) 
0 
 
20 (12.4) 
141 (87) 
1 (0.62) 
 
21 (12.8) 
141 (86) 
2 (1.1) 
 
165 (21) 
587 (74.7) 
34 (4.3) 
<0.001 
Education‡ 
High School (SD) 
College (SD) 
 
 
86.5% (3.4) 
23.7% (8.9) 
 
86.9% (3.4) 
21.4% (7.3) 
 
85% (1.8) 
24.1 %(6.1) 
 
85.8% (2.4) 
24.6% (6.6) 
 
86.9% (3.7) 
24.6% (10.2) 
 
<0.001 
<0.001 
Follow-Up Time 
Mean (days) 
Median (days) 
 
501.8 
272 
 
489.5 
211.5 
 
647 
505.5 
 
611.2 
386 
 
489.5 
211.5 
0.0002 
 
*Data points reported as N (%) unless specified otherwise.  Data may not add up to 100% due to 
rounding. 
†Metropolitan status 
‡Education level describes the percent of the population that graduated from high school or 
college. This information was based on county level census data. 
 
Table 2: Study Clinical Variables by Insurance at Diagnosis* 
 
Variable  Total  
Sample 
(n=1462) 
IN-BCCP 
 
(n=350) 
Medicaid 
 
(n=162) 
Medicare 
 
(n=164) 
Private  
Insurance 
(n=786) 
P-
value 
 
 
Stage  
0 
I -II 
III 
 
249 (17.3) 
948 (65.8) 
242 (16.8) 
 
 
 
46(13.6) 
202 (59.6) 
91 (26.8) 
 
13 (8.3) 
111 (71.2) 
32 (20.5) 
 
28 (17.5) 
100 (62.5) 
32 (20) 
 
162 (20.6) 
535 (68.2) 
87 (11.1) 
 
<0.001 
Estrogen 
No 
Yes 
Unknown 
 
 
241 (16.5) 
793 (54.2) 
428 (29.3) 
 
59 (14.9) 
138 (41.4) 
153 (43.7) 
 
28 (10.5) 
114 (77.2) 
20 (12.4) 
 
37 (15.9) 
91 (62.2) 
36 (22) 
 
117 (10.6) 
450 (61.9) 
219 (27.9) 
<0.001 
Progesterone 
No 
Yes 
Unknown 
 
360 (24.6) 
656 (44.9) 
446 (30.5) 
 
 
74 (22.6) 
119 (32.6) 
157 (44.9) 
 
50 (30.9) 
91 (56.2) 
21 (13) 
 
50 (30.5) 
74 (45.1) 
40 (24.4) 
 
186 (24.1) 
372 (47) 
228 (29) 
<0.001 
Her 2† 
No 
Yes  
Unknown 
 
634 (51.8) 
177 (14.5) 
413 (33.7) 
 
97 (31.9) 
51 (16.8) 
156 (51.3) 
 
104 (69.8) 
23 (15.4) 
22 (14.8) 
 
82 (60.3) 
19 (14) 
35 (25.7) 
 
343 (55) 
83 (13.3) 
198 (31.7) 
<0.001 
 
*Data points reported as N (%) unless specified otherwise. Total sample size for each variable 
may not add up to 1462 due to missing data. Data may not add up to 100% due to rounding. 
† This variable excludes patients with Ductal Carcinoma In-Situ. 
 
Table 3: Comparison of Surgical Management and Radiation among Insurance Types* 
Characteristic Total 
Sample 
(n=1462) 
IN-BCCP 
 
(n=350) 
Medicaid  
 
(n=162) 
Medicare 
 
(n=164) 
Private  
Insurance 
(n=786) 
P 
Value 
Surgery 
None 
BCS 
Mastectomy 
 
83 (5.7) 
706 (48.3) 
672 (46) 
 
24 (6.9) 
172 (49.1) 
154 (44) 
 
 
11 (6.8) 
64 (39.5) 
87 (53.7) 
 
18 (11) 
73 (44.5) 
73 (44.5) 
 
30 (3.8) 
397 (50.6) 
358 (45.6) 
0.004 
Radiation therapy 
No  
Yes 
 
961 (65.9) 
498 (34.1) 
 
221 (63.1) 
129 (36.9) 
 
106 (65.8) 
55(34.2) 
 
108 (66.3) 
55 (33.7) 
 
526 (67) 
259 (33) 
0.738 
BCS only† 
BCS + Radiation 
351 (49.8) 
354 (50.2) 
83(48.3) 
89 (51.7) 
32(50) 
32(50) 
34 (46.6) 
39 (53.4) 
202 (51) 
194 (49) 
0.873 
 
* Data points reported as N (%) unless specified otherwise.  Data may not add up to 100% due to 
rounding. 
†This row only evaluated patients who underwent BCS. One patient excluded due to missing 
data.  
 
Table 4: Multivariable Mixed Effect Model evaluating All-cause Mortality 
Variables Hazard Ratio [95% CI] p-value 
Insurance 
Private 
No insurance (IN-BCCP) 
Medicaid 
Medicare 
 
REF 
2.2 (1.3, 3.6) 
1.4 (0.9, 2.2) 
1.4 (0.8, 2.6) 
 
 
 
0.003 
0.216 
0.257 
 
Race 
White  
Black 
 
REF 
1 (0.7, 1.5) 
 
 
0.993 
 
 
Poverty Level 
Low 
Medium 
High 
 
REF 
1.0 (0.5, 1.8) 
1.4 (0.7, 2.9) 
 
 
 
0.865 
0.345 
 
 
Education* 
High school Diploma 
College Degree 
 
 
1.0 (0.9, 1.1) 
1.0 (0.9, 1.0) 
 
 
0.588 
0.875 
Metropolitan Status 
Rural 
Urban 
Unknown 
 
REF 
0.8 (0.5, 1.5) 
0.3 (0, 3.0) 
 
 
 
 
0.482 
0.313 
 
 
Surgery 
BCS 
Mastectomy  
No Surgery 
 
 
REF 
1.0 (0.7, 1.6) 
2.9 (1.5, 5.9) 
 
 
 
 
0.878 
0.002 
 
Radiation therapy 
No 
Yes 
 
REF 
0.7 (0.4, 1.2) 
 
 
 
0.188 
Stage 
Stage III  
Stage I and II 
 
REF 
0.4 (0.3, 0.6) 
 
 
 
0.001 
 
Comorbidities 
0 
1-2 
≥3 
 
REF 
2.1 (1.0, 4.5) 
2.6 (1.5, 4.5) 
 
 
0.053 
0.001 
  
 
 
*Educational attainment compared percent of county residents that had completed college or high 
school to counties that had 1% lower county level education attainment. This information was retrieved 
from census level data.  
 
